obicetrapib 10 mg + ezetimibe 10 mg FDC daily for coronary artery disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 12 Mar 2024: Trial registered, NCT06305559
  2. 16 May 2024: Trial started, NCT06305559

The trials

NCT06305559: A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

State
Under way
Phase
Phase 3
People
300 planned
Started
16 May 2024
Primary completion
Nov 2027
Arms
Obicetrapib/Ezetimibe
Results
None posted
  1. 12 Mar 2024: Trial registered
  2. 16 May 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.